We are live on ! Find out more
VTVT icon

vTv Therapeutics
VTVT

37 hedge funds and large institutions have $20.4M invested in vTv Therapeutics in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more capital invested

Capital invested by funds: $18M → $20.4M (+$2.42M)

0.05% less ownership

Funds ownership: 0.94% → 0.88% (-0.05%)

5% less funds holding

Funds holding: 39 → 37 (-2)

10% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 10

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

Holders
37
Holders Change
-2
Holders Change %
-5.13%
% of All Funds
0.92%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
9
Reduced
10
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$412K
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$18.5K
3
BlackRock
BlackRock
New York
+$13.6K
4
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
+$13.2K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$9.17K

Top Sellers

Rank Fund Capital Flow
1
Ameriprise
Ameriprise
Minnesota
-$454K
2
SM
Sabby Management
Florida
-$282K
3
EIM
Essex Investment Management
Massachusetts
-$198K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$145K
5
Deutsche Bank
Deutsche Bank
Germany
-$125K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
26
Wells Fargo
California
$7K +$2.39K +12 +60%
FAM
27
Fred Alger Management
New York
$6K +$4.98K +25 New
BNP Paribas Financial Markets
28
BNP Paribas Financial Markets
France
$5.33K -$399 -2 -8%
AG
29
Advisor Group
Arizona
$5K – – –
Legal & General Group
30
Legal & General Group
United Kingdom
$5K – – –
Royal Bank of Canada
31
Royal Bank of Canada
Ontario, Canada
$4K +$2.99K +15 New
Barclays
32
Barclays
United Kingdom
$3K -$2.19K -11 -48%
AIP
33
Ameritas Investment Partners
Nebraska
$2K – – –
Bank of America
34
Bank of America
North Carolina
$2K – – –
UBS Group
35
UBS Group
Switzerland
$1K -$399 -2 -25%
EIM
36
Essex Investment Management
Massachusetts
– -$198K -994 Closed
SG Americas Securities
37
SG Americas Securities
New York
– -$64K -321 Closed
Millennium Management
38
Millennium Management
New York
– -$61K -307 Closed
PCM
39
Prelude Capital Management
New York
– -$57K -285 Closed
TRCT
40
Tower Research Capital (TRC)
New York
– -$8K -42 Closed
MAM
41
Meeder Asset Management
Ohio
– -$4K -20 Closed
WAM
42
Wealthspire Advisors (Maryland)
Maryland
– +$199 +1 New
PWM
43
Perigon Wealth Management
California
– +$399 +2 New
1
2

VTVT Hedge Fund Activity: Q3 2017 in Review

37 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q3 2017, worth a combined $20.4M — up 13% from $18M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of VTVT and 5 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 9 added.

The largest buyer was JP Morgan Chase, opening a new position worth an estimated $412K. The largest seller was Ameriprise, cutting an estimated $454K.

  • 37 institutional investors held vTv Therapeutics (VTVT) as of Q3 2017, down from 39 in Q2 2017.
  • Funds reported $20.4M of vTv Therapeutics stock for Q3 2017, up 13% quarter-over-quarter.
  • 5 funds opened new vTv Therapeutics positions in Q3 2017 and 7 closed out, a net change of -2 holders.
  • The largest vTv Therapeutics buyer in Q3 2017 was JP Morgan Chase, an estimated $412K added.
  • The largest vTv Therapeutics seller in Q3 2017 was Ameriprise, an estimated $454K sold.

Based on aggregated 13F filings for Q3 2017.